Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)
Clinical trial NCT00255034 · TERMINATED
Trial details
- NCT number
- NCT00255034
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2005-02-01
- Primary completion
- 2008-06-01
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.